Oxford Biomedica Stock Value
Oxford Biomedica Company Info
EPS Growth 5Y
-30,99%
Market Cap
£0,67 B
Long-Term Debt
£0,04 B
Annual earnings
N/A
Dividend
£0,00
Dividend Yield
0,00%
Founded
1996
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
£8,03
45.74%
Last Update: 03/31/2026
Analysts: 7
Highest Price Target £11,70
Average Price Target £8,03
Lowest Price Target £5,50
In the last five quarters, Oxford Biomedica’s Price Target has risen from £3,14 to £5,33 - a 69,75% increase. Three analysts predict that Oxford Biomedica’s share price will increase in the coming year, reaching £8,03. This would represent an increase of 45,74%.
Top growth stocks in the health care sector (5Y.)
What does Oxford Biomedica do?
Oxford Biomedica plc is a gene and cell therapy company that focuses on proprietary therapeutic treatments and providing contract development and manufacturing organization (CDMO) services. The company specializes in the development and manufacturing of lentiviral vectors for various gene therapies, which serve as a platform for delivering therapeutic factors directly into patients' cells. The company offers cell and gene technologies in the biopharmaceutical sector.
Business Segments
The comp...
Oxford Biomedica Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Biopharmaceutical Partnerships:** 60%
**Cell and Gene Therapy:** 25%
**Licensing Fees and Milestone Payments:** 15%
**TOP 3 Markets:**
**USA:** 45%
**Europe:** 35%
**Asia:** 20%
Oxford Biomedica plc generates the majority of its revenue through biopharmaceutical partnerships, accou...
At which locations are the company’s products manufactured?
**Production Sites:**
- **Headquarters and Production Facility:** Oxford, United Kingdom
- **Additional Production Facilities:** United Kingdom
Oxford Biomedica plc is a leading company in the field of cell and gene therapy. The company operates its main production facilities in Oxford, United King...
What strategy does Oxford Biomedica pursue for future growth?
**Strategic Partnerships:** Expansion and Diversification (2026)
**Focus on Cell and Gene Therapy:** Expansion of Production Capacities (2026)
**Research and Development:** Increase in Investments (2026)
Oxford Biomedica plc is pursuing a growth strategy that heavily relies on strategic partnersh...
Which raw materials are imported and from which countries?
**Main raw materials:** Cell culture media, Viral vectors, Biological reagents
**Countries of origin:** USA, Germany, China
Oxford Biomedica plc is a leading company in the field of gene therapy, specializing in the development and production of viral vectors. The main raw materials imported by t...
How strong is the company’s competitive advantage?
**Market Share:** Estimated at 10-15% in the field of cell and gene therapy (2026)
**R&D Investments:** Over 20% of revenue (2025)
**Partnerships:** Several strategic alliances with leading pharmaceutical companies (by 2026)
Oxford Biomedica plc has established itself as one of the leading...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** approximately 60% (estimated for 2026 based on historical data)
**Insider Purchases/Sales:** No specific data available for 2026
The institutional investor share at Oxford Biomedica plc traditionally stands at around 60%, based on the latest available data and typ...
What percentage market share does Oxford Biomedica have?
**Market share of Oxford Biomedica plc:** Estimated 3% (2026)
**Top competitors and their market shares:**
1. **Novartis AG:** 15%
2. **Roche Holding AG:** 12%
3. **Gilead Sciences, Inc.:** 10%
4. **Pfizer Inc.:** 8%
5. **Biogen Inc.:** 7%
6. **Oxford Biomedica plc:** 3%
7. **Sangamo Therapeutics,...
Is Oxford Biomedica stock currently a good investment?
**Revenue Growth:** 10% (2025)
**Research and Development Ratio:** 25% of revenue (2025)
**Partnerships:** Collaboration with leading pharmaceutical companies such as Novartis and AstraZeneca
Oxford Biomedica plc recorded a revenue growth of 10% in 2025, driven by increasing demand for their cell a...
Does Oxford Biomedica pay a dividend – and how reliable is the payout?
**Dividend payment:** No dividend (as of 2026)
Oxford Biomedica plc has not paid any dividends to its shareholders in the past. The company operates in the field of cell and gene therapy and typically reinvests its profits into research and development as well as expanding its production capacities...
